Pfizer and Novartis are in a dead heat to become the first vaccinemaker to roll out a meningitis B vaccine for the U.S. market. But the New York pharma giant just became the first of the two to snag a decision date from the FDA, which says it will have an answer on Pfizer's candidate within the next 6 months.
Pfizer's Prevnar 13, the world's best-selling vaccine, scored a big win Wednesday, nabbing a CDC committee nod for universal use in adults over the age of 65. And once payer coverage kicks in, that's a nod that could be worth $2 billion for Pfizer, analysts say--with Merck's Pneumovax getting a boost, too.
Let the uptake begin. Pfizer has snagged the CDC panel recommendation for Prevnar 13 it's been looking for--a nod for use in adults over the age of 65. And that should result in a sales lift that analysts say could touch $2 billion in peak additional sales potential--for now.
AstraZeneca has launched a Phase III test of its targeted IL-13 asthma drug tralokinumab, beefing up its late-stage pipeline for respiratory diseases and squaring off against some major league competition now in the clinic.
Eliquis, the third entrant in the next-gen anticoagulant market, got off to a sluggish start. But now, marketers Bristol-Myers Squibb and Pfizer are pulling out all the stops when it comes to promoting the drug and expanding access
Eliquis, Pfizer and Bristol-Myers Squibb's new-age anticoagulant, got off to somewhat of a rocky start. The third entrant in the warfarin replacement market, the drug lagged well behind competitors last year, with EP Vantage estimating in October that analysts' 2014 sales estimates had fallen 60% within 12 months. Now, however, the drug is finally showing signs of life.
Pfizer is reaching out to the Google-backed genomics outfit 23andMe to better understand the root causes of inflammatory bowel disease, looking to mine patient data for clues that could bolster its growing pipeline.
Sales of Lipitor, the best-selling drug of all time, may be waning, but litigation over the cholesterol fighter is growing--a lot.
Sales of Pfizer's best-selling vaccine may soon be getting bigger. The European Medicines Agency (EMA) has accepted the company's application to expand the label on Prevenar 13 in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes the vaccine contains.
Pfizer has cleared the decks of a marketing scandal that it inherited with its 2009 acquisition of Wyeth. The New York drugmaker will pay $35 million to 41 states and the District of Columbia to settle a case accusing it of pushing a kidney transplant drug for off-label uses.